Journal article
Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting
- Abstract:
-
Relapsed or refractory classical Hodgkin lymphoma (cHL) is associated with a poor outcome when standard chemotherapy fails. Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody-drug conjugate licensed for use at relapse after autologous stem cell transplant (ASCT) or following two prior therapies in those unsuitable for ASCT. There are limited data assessing the ability of BV to enable curative SCT. We performed a UK-wide retrospective study of 99 SCT-naïve relapsed/refractory cHL. Al...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 270.3KB)
-
(Accepted manuscript, pdf, 31.1KB)
-
- Publisher copy:
- 10.1111/bjh.14898
Authors
Funding
Julian Starmer-Smith lymphoma fund
More from this funder
National Institute for Health Research Biomedical Research Centre Programme
More from this funder
Bibliographic Details
- Publisher:
- Wiley Publisher's website
- Journal:
- British Journal of Haematology Journal website
- Volume:
- 179
- Issue:
- 3
- Pages:
- 471-479
- Publication date:
- 2017-08-31
- Acceptance date:
- 2017-07-18
- DOI:
- EISSN:
-
1365-2141
- ISSN:
-
0007-1048
- Pmid:
-
28857136
- Source identifiers:
-
725854
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:725854
- UUID:
-
uuid:db8a45c6-e6e1-4263-aba2-c8c8d3b8abc2
- Local pid:
- pubs:725854
- Deposit date:
- 2017-09-13
Terms of use
- Copyright holder:
- John Wiley & Sons Ltd
- Copyright date:
- 2017
- Notes:
-
© 2017 John Wiley & Sons Ltd. This is the author accepted manuscript following peer review version of the article. The final version is
available online from Wiley at: https://doi.org/10.1111/bjh.14898
Note: an erratum exists for this article, originally published and available at: https://doi.org/10.1111/bjh.15103
If you are the owner of this record, you can report an update to it here: Report update to this record